Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Memory Pharmaceuticals Corp.

This article was originally published in Start Up

Executive Summary

Memory Pharmaceuticals intends to discover and develop drugs to treat mild-to-moderate dementia caused by disease, traumatic injury, or aging. Its technology is based on the work of Dr. Eric Kandel, one of the pioneers in discovering the molecular mechanisms of long-term memory formation.

You may also be interested in...



Memories: Ditching De Novo Discovery

Drug development start-ups like Sention and David Pharmaceuticals are hoping to eliminate or reduce the safety risk inherent in drug development by identifying compounds Big Pharma has shelved or incorporated into marketed drugs and which are thought to be safe in humans. Instead of starting from scratch with de novo discovery of new molecules, they are focusing on in-licensing either promising compounds or marketed products that could benefit from incremental improvements.

Tackling Genomics of the Brain

With the limited success of traditional approaches to CNS, scientists are betting that genomics may hold the key to a new generation of drugs that stop disease progression and possibly reverse its impact. At least half a dozen companies focusing mostly on neurogenomics have started up and raised more than $100 million in the past three years. While they use standard genomics tools and follow typical post-genomics business models, they face special challenges due to the complexity of the brain.

In Vivo's Deals Of The Month, February 2018

In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel